Pulmonary sarcoidosis

Clinics in Chest Medicine

Volumn 25, Issue 3, 2004, Pages 521-530

  Baughman, Robert P ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; PENTOXIFYLLINE; PREDNISONE; THALIDOMIDE;

ANAMNESIS; ANAPHYLAXIS; BLADDER CANCER; BONE MARROW SUPPRESSION; BRONCHOSCOPY; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CYSTITIS; DIABETES MELLITUS; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ERUPTION; DYSPNEA; EYE DISEASE; HEPATITIS; HUMAN; HYPERTENSION; IMAGE ANALYSIS; INFECTION; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LABORATORY TEST; LEUKOPENIA; LUNG BIOPSY; LUNG FIBROSIS; LUNG LAVAGE; LYMPHOCYTE COUNT; MEDIASTINOSCOPY; MEDICAL ASSESSMENT; NAUSEA; NEEDLE BIOPSY; PATIENT; PHYSICAL EXAMINATION; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; SARCOIDOSIS; SIDE EFFECT; SOMNOLENCE; SYMPTOM; TERATOGENICITY; THORAX RADIOGRAPHY; TOXICITY; TREATMENT INDICATION; WEIGHT GAIN;

ANTIBODIES, MONOCLONAL; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; HUMANS; SARCOIDOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4344679827     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2004.04.006     Document Type: Review

References (90)

1. Baughman R.P., Teirstein A.S., Judson M.A., et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 164:2001;1885-1889
2. Baughman R.P., Winget D.B., Bowen E.H., et al. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis. 14:1997;154-158
3. ACCESS Research Group Design of a case controlled etiologic study of sarcoidosis (ACCESS). J Clin Epidemiol. 52:1999;1173-1186
4. Freemer M., King T.E. Jr. The ACCESS study: characterization of sarcoidosis in the United States. Am J Respir Crit Care Med. 164:2001;1754-1755
5. Reich J.M., Johnson R.E. Course and prognosis of sarcoidosis in a nonreferral setting: analysis of 86 patients observed for 10 years. Am J Med. 78:1985;61-67
6. Loddenkemper R., Kloppenborg A., Schoenfeld N., et al. Clinical findings in 715 patients with newly detected pulmonary sarcoidosis: results of a cooperative study in former West Germany and Switzerland. WATL Study Group: Wissenschaftliche Arbeitsgemeinschaft für die Therapie von Lungenkrankheiten. Sarcoidosis Vasc Diffuse Lung Dis. 15:1998;178-182
7. Pietinalho A., Ohmichi M., Hiraga Y., et al. The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan: a comparative analysis of 571 Finnish and 686 Japanese patients. Sarcoidosis. 13:1996;159-166
8. Watters L.C., King T.E., Schwarz M.I., et al. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis. 133:1986;97-103
9. Baughman R.P., Iannuzzi M.C., Lower E.E., et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 19:2002;198-204
10. Shorr A.F., Torrington K.G., Hnatiuk O.W. Endobronchial involvement and airway hyperreactivity in patients with sarcoidosis. Chest. 120:2001;881-886
11. Highland K.B., Retalis P., Coppage L., et al. Is there an anatomic explanation for chest pain in patients with pulmonary sarcoidosis? South Med J. 90:1997;911-914
12. Scadding J.G. Prognosis of intrathoracic sarcoidosis in England. BMJ. 4:1961;1165-1172
13. Remy-Jardin M., Giraud F., Remy J., et al. Pulmonary sarcoidosis: role of CT in the evaluation of disease activity and functional impairment and in prognosis assessment. Radiology. 191:1994;675-680
14. Hunninghake G.W., Costabel U., Ando M., et al. ATS/ERS/WASOG statement on sarcoidosis: American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 16:1999;149-173
15. Lower E.E., Hawkins H.H., Baughman R.P. Breast disease in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 18:2001;301-306
16. Daly P.A., O'Brian D.S., Robinson I., et al. Hodgkin's disease with a granulomatous pulmonary presentation mimicking sarcoidosis. Thorax. 43:1988;407-409
17. Baughman R.P., du Bois R.M., Lower E.E. Sarcoidosis. Lancet. 361:2003;1111-1118
18. Judson M.A., Thompson B.W., Rabin D.L., et al. The diagnostic pathway to sarcoidosis. Chest. 123:2003;406-412
19. Lenner R., Schilero G.J., Padilla M.L., et al. Sarcoidosis presenting in patients older than 50 years. Sarcoidosis Vasc Diffuse Lung Dis. 19:2002;143-147
20. Hillerdal G., Nou E., Osterman K., et al. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis. 130:1984;29-32
21. Tambouret R., Geisinger K.R., Powers C.N., et al. The clinical application and cost analysis of fine-needle aspiration biopsy in the diagnosis of mass lesions in sarcoidosis. Chest. 117:2000;1004-1011
22. Leonard C., Tormey V.J., O'Keane C., et al. Bronchoscopic diagnosis of sarcoidosis. Eur Respir J. 10:1997;2722-2724
23. Trisolini R., Agli L.L., Cancellieri A., et al. The value of flexible transbronchial needle aspiration in the diagnosis of stage I sarcoidosis. Chest. 124:2003;2126-2130
24. Wang K.P., Fuenning C., Johns C.J. Flexible transbronchial needle aspiration for the diagnosis of sarcoidosis. Ann Otol Rhinol Laryngol. 98:1989;298-300
25. Fritscher-Ravens A., Sriram P.V., Topalidis T., et al. Diagnosing sarcoidosis using endosonography-guided fine-needle aspiration. Chest. 118:2000;928-935
26. Poulter L.W., Rossi G.A., Bjermer L., et al. The value of bronchoalveolar lavage in the diagnosis and prognosis of sarcoidosis. Eur Respir J. 3:1990;943-944
27. Kantrow S.P., Meyer K.C., Kidd P., et al. The CD4/CD8 ratio in BAL fluid is highly variable in sarcoidosis. Eur Respir J. 10:1997;2716-2721
28. Baughman R.P., Drent M. Role of bronchoalveolar lavage in interstitial lung disease. Clin Chest Med. 22:2001;331-341
29. Hunninghake G.W., Crystal R.G. Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med. 305:1981;429-432
30. Baughman R.P. Sarcoidosis: usual and unusual manifestations. Chest. 94:1988;165-170
31. Drent M., Wagenaar S.S., Mulder P.H., et al. Bronchoalveolar lavage fluid profiles in sarcoidosis, tuberculosis, and non-Hodgkin's and Hodgkin's disease: an evaluation of differences. Chest. 105:1994;514-519
32. Winterbauer R.H., Lammert J., Selland M., et al. Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis. Chest. 104:1993;352-361
33. Ward K., O'Connors C., Odlun C., et al. Prognostic value of bronchoalveolar lavage in sarcoidosis: the critical influence of disease presentation. Thorax. 44:1989;6-12
34. Ceuppens J.L., Lacquet L.M., Marien G., et al. Alveolar T-cell subsets in pulmonary sarcoidosis: correlation with disease activity and effect of steroid treatment. Am Rev Respir Dis. 129:1984;563-568
35. Drent M., Jacobs J.A., Cobben N.A., et al. Computer program supporting the diagnostic accuracy of cellular BALF analysis: a new release. Respir Med. 95:2001;781-786
36. Shorr A.F., Torrington K.G., Hnatiuk O.W. Endobronchial biopsy for sarcoidosis: a prospective study. Chest. 120:2001;109-114
37. Koerner S.K., Sakowitz A.J., Appelman R.I., et al. Transbronchial lung biopsy for the diagnosis of sarcoidosis. N Engl J Med. 293:1975;268-270
38. Koonitz C.H., Joyner L.R., Nelson R.A. Transbronchial lung biopsy via the fiberoptic bronchoscope in sarcoidosis. Ann Intern Med. 85:1976;64-66
39. Halme M., Piilonen A., Taskinen E. Comparison of endobronchial and transbronchial biopsies with high-resolution CT (HRCIT) in the diagnosis of sarcoidosis. APMIS. 109:2001;289-294
40. Chapman J.T., Mehta A.C. Bronchoscopy in sarcoidosis: diagnostic and therapeutic interventions. Curr Opin Pulm Med. 9:2003;402-407
41. Baughman R.P., Dohn M.N., Loudon R.G., et al. Bronchoscopy with bronchoalveolar lavage in tuberculosis and fungal infections. Chest. 99:1991;92-97
42. Hunninghake G.W., Zimmerman M.B., Schwartz D.A., et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 164:2001;193-196
43. rd edition:2000;725-780 WB Saunders Co., Philadelphia
44. Hunninghake G.W., Costabel U., Ando M., et al. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 16:1999;149-173
45. Gibson G.J., Prescott R.J., Muers M.F., et al. British Thoracic Society sarcoidosis study: effects of long term corticosteroid treatment. Thorax. 51:1996;238-247
46. Paramothayan S., Jones P.W. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA. 287:2002;1301-1307
47. Baughman R.P., Shipley R., Eisentrout C.E. Predictive value of gallium scan, angiotensin-converting enzyme level, and bronchoalveolar lavage in two-year follow-up of pulmonary sarcoidosis. Lung. 165:1987;371-377
48. Gottlieb J.E., Israel H.L., Steiner R.M., et al. Outcome in sarcoidosis: the relationship of relapse to corticosteroid therapy. Chest. 111:1997;623-631
49. Rizzato G., Montemurro L., Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis. 15:1998;52-58
50. Baughman R.P., Iannuzzi M.C., Lower E.E., et al. The use of fluticasone for acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 19:2002;198-204
51. Research Committee of the British Tuberculosis Association Chloroquine in the treatment of sarcoidosis. Tubercle. 48:1967;257-272
52. Siltzbach L.E., Teirstein A.S. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand. 425:1964;302S-308S
53. Baltzan M., Mehta S., Kirkham T.H., et al. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med. 160:1999;192-197
54. Bartel P.R., Roux P., Robinson E., et al. Visual function and long-term chloroquine treatment. S Afr Med J. 84:1994;32-34
55. Jones S.K. Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol. 140:1999;3-7
56. Mazzuca S.A., Yung R., Brandt K.D., et al. Current practices for monitoring ocular toxicity related to hydroxychloroquine (Plaquenil) therapy. J Rheumatol. 21:1994;59-63
57. Baughman R.P., Lower E.E. A clinical approach to the use of methotrexate for sarcoidosis. Thorax. 54:1999;742-746
58. Lower E.E., Baughman R.P. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 155:1995;846-851
59. Lower E.E., Broderick J.P., Brott T.G., et al. Diagnosis and management of neurologic sarcoidosis. Arch Intern Med. 157:1997;1864-1868
60. Vucinic V.M. What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med. 8:2002;470-476
61. Gedalia A., Molina J.F., Ellis G.S., et al. Low-dose methotrexate therapy for childhood sarcoidosis. J Pediatr. 130:1997;25-29
62. Dev S., McCallum R.M., Jaffe G.J. Methotrexate for sarcoid-associated panuveitis. Ophthalmology. 106:1999;111-118
63. Baughman R.P., Winget D.B., Lower E.E. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis. 17:2000;60-66
64. Zisman D.A., McCune W.J., Tino G., et al. Drug-induced pneumonitis: the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis. 18:2001;243-252
65. Baughman R.P., Koehler A., Bejarano P.A., et al. Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis. Arch Intern Med. 163:2003;615-620
66. Muller-Quernheim J., Kienast K., Held M., et al. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J. 14:1999;1117-1122
67. Kataria Y.P. Chlorambucil in sarcoidosis. Chest. 78:1980;36-42
68. Baughman R.P., Lower E.E. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 21:2004;43-48
69. Talar-Williams C., Hijazi Y.M., Walther M.M., et al. Cyclophosphamide- induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 124:1996;477-484
70. Confavreux C., Saddier P., Grimaud J., et al. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology. 46:1996;1607-1612
71. Lamers C.B., Griffioen G., Van H.R., et al. Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease. Scand J Gastroenterol. 230:1999;111-115
72. Martinet Y., Pinkston P., Saltini C., et al. Evaluation of the in vitro and in vivo effects of cyclosporine on the lung T-lymphocyte alveolitis of active pulmonary sarcoidosis. Am Rev Respir Dis. 138:1996;1242-1248
73. Wyser C.P., van Schalkwyk E.M., Alheit B., et al. Treatment of progressive pulmonary sarcoidosis with cyclosporin A: a randomized controlled trial. Am J Respir Crit Care Med. 156:1997;1571-1576
74. Zabel P., Entzian P., Dalhoff K., et al. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med. 155:1997;1665-1669
75. Bachelez H., Senet P., Cadranel J., et al. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol. 137:2001;69-73
76. Eishi Y., Suga M., Ishige I., et al. Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J Clin Microbiol. 40:2002;198-204
77. Le C.H., Morales A., Trentham D.E. Minocycline in early diffuse scleroderma. Lancet. 352:1998;1755-1756
78. Carlesimo M., Giustini S., Rossi A., et al. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol. 32:1995;866-869
79. Baughman R.P., Judson M.A., Teirstein A.S., et al. Thalidomide for chronic sarcoidosis. Chest. 122:2002;227-232
80. Baughman R.P., Strohofer S.A., Buchsbaum J., et al. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med. 115:1990;36-42
81. Ziegenhagen M.W., Rothe E., Zissel G., Muller-Quernheim J. Exaggerated TNF-alpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 19:2002;185-190
82. Baughman R.P., Iannuzzi M. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy. BioDrugs. 17:2003;425-431
83. Jack D. 54-week results on infliximab attract attention at EULAR: European League against Rheumatism. Lancet. 353:1999;2132
84. Konrad A., Seibold F. Response of cutaneous Crohn's disease to infliximab and methotrexate. Dig Liver Dis. 35:2003;351-356
85. Lovell D.J., Giannini E.H., Reiff A., et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis: Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 342:2000;763-769
86. Baughman R.P., Lower E.E. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 18:2001;70-74
87. Yee A.M.F., Pochapin M.B. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis-alpha therapy. Ann Intern Med. 135:2001;27-31
88. Utz J.P., Limper A.H., Kalra S., et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 124:2003;177-185
89. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor-alpha neutralizing agent. N Engl J Med. 345:2001;1098-1104
90. Pietinalho A., Ohmichi M., Lofroos A.B., et al. The prognosis of sarcoidosis in Finland and Hokkaido, Japan: a comparative five-year study of biopsy-proven cases. Sarcoidosis Vasc Diffuse Lung Dis. 17:2000;158-166